About ADL

This author has not yet filled in any details.
So far ADL has created 23 blog entries.

Lantern Pharma Chief Scientific Officer Gregory Tobin to Speak at TMED 10: Disruptive Innovation in Healthcare Conference

By |2019-09-04T18:13:28+00:00September 4th, 2019|

Lantern Pharma Press Release Lantern Pharma Chief Scientific Officer Gregory Tobin to Speak at TMED 10: Disruptive Innovation in Healthcare Conference Dr. Tobin will discuss the role of genomic biomarkers and signatures in the development of Lantern’s portfolio of oncology therapeutics at a leading international conference in translational and personalized medicine.  Press Release [...]

Global Precision Medicine Market Research Report – 2025 Top Companies

By |2019-08-05T20:14:29+00:00June 19th, 2019|

Global Precision Medicine Market Research Report - 2025 Top Companies Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the [...]

Lantern Pharma Announces Multiple Presentations at AACR 2019

By |2020-02-19T18:17:02+00:00March 29th, 2019|

Lantern Pharma Announces Multiple Presentations at AACR 2019 FOR IMMEDIATE RELEASE Friday, March 29 - 2019 Lantern Pharma announces multiple presentations at AACR 2019 highlighting advancements of its precision oncology pipeline of therapeutics using their AI-based platform, RADR™,to identify gene signatures that predict potential response of patient’s tumor to a drug. [...]

Precision Oncology Company Lantern Pharma’s Artificial Intelligence Approach

By |2019-08-05T20:11:57+00:00April 16th, 2018|

Precision Oncology Company Lantern Pharma's Artificial Intelligence Approach NEW YORK--(BUSINESS WIRE)--Lantern Pharma is applying Artificial Intelligence (AI) to tailor multiple promising precision drug programs to the right cancer patients through use of their RADRTM platform (Response Algorithm for Drug Rescue and Positioning).

Lantern Pharma Joins Genomics England to Advance Their Precision Oncology Platform

By |2019-08-05T20:07:07+00:00February 26th, 2018|

DALLAS--(BUSINESS WIRE)--Genomics England and Lantern Pharma, a clinical stage pharma company specializing in precision oncology using artificial intelligence, announced today that Lantern will join Genomics England’s Discovery Forum industry partnership. The partnership aims to translate groundbreaking research into innovative treatments, and ultimately patient benefit, as rapidly as possible.